Novo Nordisk A/S Common Stock (NVO)

Pfizer's deal with the Trump administration raised hopes that the European company wouldn't be subject to 100% tariffs on certain imported drugs.

As the third quarter of 2025 draws to a close, the financial markets are abuzz with the exceptional performances of several S&P 500 companies. While official data is still being compiled, preliminary assessments and prevailing market trends suggest a cohort of innovative giants and agile disruptors have delivered significant

New York, NY – September 30, 2025 – Shares of pharmaceutical giant Pfizer (NYSE: PFE) experienced a dramatic decline today, making it one of the market's bottom performers, following an unexpected and significant setback in its highly anticipated obesity drug pipeline. The news has sent ripples through the biopharmaceutical sector, highlighting the

But Trump might get less than he bargained for as drugmakers focus on prices abroad, rather than stateside efforts.

Political pressure on Big Pharma is one reason why the industry is underperforming in 2025.

It's hard to keep these longtime winners down for too long.

A pundit tracking the company cited several reasons why investors should sell out of it.

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1 results.

You won't need a huge amount of cash to invest in these great pharma stocks.

To gain an edge, this is what you need to know today.

September 26, 2025 – Global financial markets are once again in the throes of uncertainty as the United States unveils a fresh wave of substantial trade tariffs, set to take effect on October 1, 2025. These new duties, targeting sectors from pharmaceuticals to heavy trucks and home furnishings, signal a deepening

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Recent data from a head-to-head trial was positive for Eli Lilly, but it's not the whole story.

These stocks come with some uncertainty, but they have strong fundamentals and trade at low earnings multiples.

There's an opportunity to get in on the weight-loss drug craze at a reasonable price.

The latest data from the company's oral weight loss drug is bullish for the stock.

The pharmaceutical leader is gradually laying the groundwork for a strong rebound.

Shares tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug.

As the global economy marches towards the final quarter of 2025, investors find themselves at a pivotal juncture, balancing cautious optimism with an awareness of lingering uncertainties. Moderating inflation, divergent central bank policies, and persistent geopolitical tensions define a landscape where careful stock selection is paramount. Against this backdrop, five